Inotiv, Inc. announced an agreement to partner with Japan-based PhoenixBio Co., Ltd., to provide research services in Inotiv's U.S. labs using PhoenixBio's proprietary PXB-mouse® research model, a liver-humanized chimeric model used for drug discovery and early development. This collaboration enhances the Inotiv portfolio and leverages the Company's extensive experience and expertise working with liver-humanized chimeric research models to enable and advance important translational research for hepatic diseases, as well as cell and gene therapy approaches where liver engagement is a key endpoint. PhoenixBio's PXB-mouse® has been the most utilized liver-humanized research model, with growing demand across a range of applications including drug metabolism and pharmacokinetics (DMPK), toxicology, and other pharmacology-related evaluations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
479 JPY | +0.42% | +0.63% | +2.79% |
1st Jan change | Capi. | |
---|---|---|
+2.79% | 12.19M | |
+0.67% | 42.4B | |
+46.06% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- 6190 Stock
- News PhoenixBio Co., Ltd.
- Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering